New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceBusiness Wire • 04/22/24
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024Business Wire • 04/16/24
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesBusiness Wire • 02/27/24
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceBusiness Wire • 02/21/24
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024Business Wire • 02/08/24
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics PlatformBusiness Wire • 01/08/24
Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to ProgressBusiness Wire • 12/01/23
Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung NodulesBusiness Wire • 11/29/23
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023Business Wire • 11/22/23
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients GloballyBusiness Wire • 11/07/23
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug DevelopmentBusiness Wire • 10/27/23